Sick Charts: Why The ASX’s 3 Pathology Stocks Are All Under the Weather

The ASX’s 3 pathology stocks: Sonic Healthcare (ASX:SHL), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL); have delivered a torrid experience for shareholders over the past two to three years.

Sonic, the global heavyweight, has fallen nearly 20% since early 2025 and recently traded at decade lows. Healius, long the sector’s problem child, has lost more than 60% of its value over three years. ACL, the smallest of the trio, sits roughly 45% below its 52‑week high. In our view, this is not coincidence. All three face the same structural headwinds, and understanding those headwinds is the starting point for any assessment of the sector.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

The 3 Reasons ASX Pathology Stocks Are Struggling

The COVID Hangover

The most important factor behind the sector’s prolonged weakness is the evaporation of COVID‑19 testing revenue. Between 2020 and 2022, pathology providers were the unlikely beneficiaries of a once‑in‑a‑generation testing boom. PCR volumes were enormous, government‑funded and priced at a premium. Sonic, with its global laboratory footprint across Australia, the United States, Germany and the United Kingdom, captured this windfall at scale. Healius and ACL benefited domestically in proportion to their market share.

When COVID testing normalised as abruptly as it did in the second half of 2022, all three operators faced a simultaneous top‑line cliff and a cost base that had expanded to serve elevated volumes. Pathology is a high fixed‑cost business; laboratories, equipment, scientific staff and collection centre networks cannot be unwound quickly. The result was severe margin compression that persisted long after the pandemic peak. Could this have been avoided? Realistically, no. The unwind was always going to be painful.

2. Medicare: The Structural Funding Problem

Beneath the COVID distortion lies a more persistent issue: chronic underfunding of Medicare pathology rebates. For roughly 24 years, most of the Pathology Services Table was not indexed to inflation. Chemical pathology items — representing 42.3% of Medicare pathology claims by dollar value — and microbiology items (16.6% of claims) remain excluded from recent partial indexation measures. The 2024–25 Federal Budget introduced indexation for some lower‑volume categories, but the core, high‑volume items remain unindexed.

The practical consequence is a sector whose revenues are structurally anchored to government‑set schedules that have declined in real terms for two decades. As the AMA argued in 2025, full indexation must be restored to prevent further threats to accessibility, affordability and safety. All three listed operators remain at the mercy of this policy environment, and advocacy from peak bodies such as Australian Pathology has yet to deliver comprehensive reform.

3. Labour Inflation and Operating Leverage

The third shared pressure is rising labour costs. Pathology is labour‑intensive: pathologists, clinical scientists, collection centre staff and couriers collectively represent the dominant cost line. As wage inflation accelerated post‑pandemic and healthcare labour markets tightened, cost‑to‑revenue ratios deteriorated across the board. Sonic, with global scale and deeper management capability, has been the most effective at managing this – reducing labour costs as a percentage of revenue by 50 basis points in H1 FY25. Healius and ACL, smaller and less diversified, have struggled more acutely.

Sonic’s FY25 results demonstrated the resilience that scale can provide. Revenue climbed 8% to A$9.6bn, net profit rose 7% to A$514m, and operating cash generation surged 21% to A$1.3bn. These are creditable outcomes in a difficult environment. Yet Sonic’s share price has still fallen meaningfully, suggesting markets are pricing in sustained margin pressure, currency headwinds and the overhang of a structurally constrained Medicare pricing regime.

Would The Proposed Healius-ACL Merger Have Helped?

In March 2023, ACL launched an unsolicited off‑market takeover bid for Healius, offering 0.74 ACL shares per Healius share — a proposal valued at approximately A$1.58bn. It was a bold move from a company with roughly half the market capitalisation of its target. ACL’s thesis was straightforward: by combining the second and third‑largest domestic pathology providers, the merged entity could extract meaningful cost synergies through laboratory consolidation, shared courier networks and reduced administrative overhead.

The bid failed for two reasons. First, Healius’ largest shareholders — Perpetual Investment Management (12.5%) and Tanarra Capital (8.5%) — opposed the deal immediately, describing it as an “inappropriate transfer of value” from Healius shareholders to ACL. The 90% acceptance threshold required for an off‑market offer was effectively impossible. Second, in December 2023, the ACCC formally opposed the merger, concluding that a combined ACL‑Healius would operate more than 50% of approved pathology collection centres nationally and, in some regions, would represent the only two providers available to patients.

The counterfactual is worth considering. With hindsight, Healius shareholders have suffered catastrophic value destruction since the deal was blocked: the share price has fallen from around A$2.20 at the time of the bid to roughly A$0.61 today — a decline of more than 70%. Had the merger proceeded, and had the combined entity extracted meaningful fixed‑cost leverage, the trajectory might have been materially different. ACL shareholders are worse off too, trading well below pre‑bid levels. Both boards are left to reflect on what might have been.

Was the ACCC’s decision correct? In theory, yes. Barriers to entry are high, scale matters and divestiture undertakings were deemed insufficient. But the observed outcome — two subscale operators struggling to generate adequate returns in a market where pricing is government‑controlled — sits uneasily with the regulator’s logic.

Recent Results in Detail: Did the Numbers Warrant A Sell‑Off?

Looking purely at the reported numbers, the market’s punishment appears, in some respects, disproportionate — particularly for Sonic and the operationally improving Healius.

Sonic’s FY25 result was strong: revenue up 8% to A$9.65bn, NPAT up 7% to A$514m, operating cash flow up 21% to A$1.3bn. Its 1H26 result was stronger still, with revenue of A$5.45bn (+17%), EBITDA of A$907m (+10%), NPAT of A$262m (+11%) and EPS of 53.1c. The company reaffirmed FY26 EBITDA guidance of A$1.87bn–A$1.95bn (constant currency) and lifted its interim dividend by 2.3% to 45c. The market rewarded the result with a 12–13% rally, yet Sonic still trades roughly 16% lower over 12 months and recently touched a decade low of A$18.88. Investors are clearly pricing in structural headwinds rather than near‑term earnings.

Healius presents a more nuanced picture. Its FY25 net loss narrowed significantly to A$151m from A$643m, and its 1H26 result showed genuine operational improvement: underlying EBITDA rose 13.1% to A$122.2m, and underlying EBIT turned positive at A$7.9m. Pathology revenue grew 3.5%, Agilex EBITDA surged 65.5%, and clinical trials revenue jumped 118.6%. The company secured a five‑year ADF contract worth approximately A$60m, commencing April 2026. Management reaffirmed FY26 guidance.

Despite this, Healius shares hit a record low on results day, falling from a 52‑week high of A$1.64 to around A$0.61 — a decline of more than 60%. The market is focused not on incremental EBIT improvement but on continued statutory losses, the absence of dividends and the slow pace of recovery.

ACL’s FY25 result was modest but positive, with statutory NPAT of A$32.8m on revenue of A$741.3m. Its 1H26 result was softer: revenue slipped to A$365.4m from A$369.2m, and NPAT fell to A$5.6m from A$11.7m. Management cited subdued market conditions and downgraded FY26 revenue guidance. ACL shares have fallen roughly 45% from their 52‑week high. Underlying EPS of 6.7c was up 12.8% due to buybacks, but the halving of reported earnings alarmed investors.

The Iran conflict, which escalated sharply in early 2026, added a macro overlay. The ASX fell more than 6% by mid‑March, wiping over A$100bn in market value. Treasury modelling suggested the conflict could add 0.5–1.25% to inflation and subtract 0.2–0.6% from GDP.

Pathology stocks, already trading on thin margins, are indirectly exposed. If inflation rises and household budgets tighten, discretionary healthcare (including routine diagnostics) is deferred. Healius noted “lower than normal episode volumes” in 1H26. In a stagflationary environment, this behavioural shift could persist.

Are Better Times Ahead?

Across all three pathology companies, the near‑term outlook remains constrained. Medicare indexation reform is incomplete. Labour markets remain tight. The COVID windfall is gone and will not return. Sonic, with global diversification and cost discipline, is best placed to navigate the cycle. Healius is attempting a turnaround from a position of weakness, with no dividend and a stretched balance sheet. ACL is profitable but subscale relative to Sonic’s entrenched position.

In our view, the sector’s common disease is structural rather than cyclical. Without full Medicare indexation, the economics of pathology collection remain fundamentally unfavourable for smaller, domestically focused operators. For investors, that is the prognosis that matters most.